

Camson Biotech delivers record growth of 814% in Q4

May 20, 2010

Camson Biotechnologies, IPR-driven agricultural biotechnology company posted a record 814% growth in the fourth quarter ended Mar. 31, 2010 on the back of rising demand for zero-residue biocides and Camson's unique hybrid seeds.

The company declared a total income of Rs 189.7 million for the quarter ended, rising 171% YoY from Rs 69.9 million in the corresponding period last year.

Camson's introduction of the hybrid ice-box watermelon and an increasing demand for biocides and bio-fertilizers that are cost-effective and also give a higher crop yield, propelled the company's annual net profit to Rs 150.1 million for the year ended Mar. 31, 2010, showing a growth of 85% from Rs 81.1 million recorded in the corresponding period last year.

Commenting on the results, Dharendra Kumar, founder and managing director (MD) Camson Biotech (Q,N,C,F)* said, "I am delighted with Camson's strong performance in this quarter and in the financial year. Our business segments continue their robust growth on the back of increasing demand for cost-effective and environmentally friendly hybrid seeds, biocides and bio-fertilizers."

He added, "Our innovations in the hybrid seeds segments have shown a strong acceptance with farmers and we are confident of sustaining this growth momentum with the introduction of path-breaking products for achieving higher yield in the coming quarters. We believe that we are bringing agriculture and biotechnology together to create food security for India and the world."

Shares of the company remained unchanged at Rs 164.10. The total volume of shares traded was 64,740 at the BSE (1.51 p.m., Thursday).